Get started
Author

Marie Castéra

Observed names: Castera, Marie, M. Castera, Marie Castera
ORCID: 0009-0005-7674-6778
Observed ORCID: 0009-0005-7674-6778
OpenAlex ID: A5108826583
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
2023 · Olivier Bylicki, Pascale Tomasini, et al. · European Journal of Cancer · 29
PDF
Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2025 · Dinu Stefan, Paul Lesueur, et al. · Clinical Cancer Research · 28
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
2022 · Elodie Coquan, Bénédicte Clarisse, et al. · BMC Cancer · 13
PDF
Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01)
2024 · Paul Lesueur, Benedicte Clarisse, et al. · BMC Cancer · 7
PDF
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial
2024 · Elodie Coquan, Nicolas Penel, et al. · Therapeutic Advances in Urology · 7
CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
2021 · Elodie Coquan, Pierre-Emmanuel Brachet, et al. · BMC Cancer · 5
PDF
Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.
2016 · Nicolas Mounier, Sabine Anthony, et al. · Journal of Clinical Oncology · 3
Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG)
2025 · Paul Lesueur, Florence Joly, et al. · Radiation Oncology · 2
PDF
2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study)
2022 · Elodie Coquan, Justine Lequesne, et al. · International Journal of Gynecological Cancer · 2
PDF
Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer.
2021 · Carmen Florescu, Justine Lequesne, et al. · Journal of Clinical Oncology · 2
Supplementary Figure 1c. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2025 · Dinu Stefan, Paul Lesueur, et al. · 1
Supplementary Figure 1b. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2025 · Dinu Stefan, Paul Lesueur, et al. · 1
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.
2023 · Dinu Stefan, Justine Lequesne, et al. · Journal of Clinical Oncology · 1
Phase II study of cabozantinib in recurrent or metastatic cervical cancer after progression on platinum-based chemotherapy (CABOCOL)
2026 · Elodie Coquan, Roman Vion, et al. · Gynecologic Oncology
Correction: Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG)
2025 · Paul Lesueur, Florence Joly, et al. · Radiation Oncology
PDF
Supplementary Table 1 from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2025 · Dinu Stefan, Paul Lesueur, et al.
Supplementary Figure 1a. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2025 · Dinu Stefan, Paul Lesueur, et al.
Supplementary Figure 2. from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2025 · Dinu Stefan, Paul Lesueur, et al.
Data from Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study
2025 · Dinu Stefan, Paul Lesueur, et al.
GFPC 06-2018 : étude de phase II, multicentrique, ouverte et non randomisée évaluant l’association sel de platine-pémétrexed-atézolizumab (±bévacizumab) pour les patients atteints d’un cancer du poumon non à petites cellules non épidermoïde de stade IIIB/IV présentant une mutation de l’EGFR, un réarrangement de l’ALK ou une fusion du ROS1 et progressant après des thérapies ciblées orales
2023 · O. Bylicki, P. Tomasini, et al. · Revue des Maladies Respiratoires Actualités
Stratégies d’accès lexical dans une épreuve de lexique élaboré : particularités de sujets Alzheimer versus témoins
2014 · M. Castera, F. Medina · Revue Neurologique
Works count: 23
Citation count: 101
H-index: 5
I10-index: 3
Year
Topic
Type